Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.38 |
| ▸ | PTGES | O14684 | 11/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12521780 | 0.96 | TRPA1 (0.41) | TRPA1PTGESTLR8TLR7CYP1A2 | |
| SCHEMBL16229462 | 0.89 | TRPA1 (0.40) | TRPA1PTGESTLR8TLR7CYP1A2 | |
| SCHEMBL1645893 | 0.87 | EGLN1 (0.42) | TRPA1PTGESTLR8TLR7CYP1A2 | |
| SCHEMBL1644817 | 0.86 | TLR8 (0.41) | TRPA1PTGESTLR8TLR7CYP1A2 | |
| SCHEMBL8306075 | 0.86 | CBFB (0.45) | TRPA1PTGESTLR8TLR7MAPT | |
| SCHEMBL13446034 | 0.86 | DHODH (0.43) | TRPA1PTGESCYP1A2MAPT | |
| SCHEMBL8299814 | 0.85 | MGAM (0.48) | CYP1A2GAAMAPT | |
| SCHEMBL8302369 | 0.84 | PTGES (0.42) | PTGESMAPT | |
| SCHEMBL14514539 | 0.84 | TRPA1 (0.39) | TRPA1PTGESTLR8TLR7CYP1A2 | |
| SCHEMBL13544998 | 0.79 | MAPT (0.39) | PTGESCYP1A2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004232-A1 | Pharmaceutical Compounds | ERBB3, ABL1, RET | TRPA1 4573/4885PTGES 3537/4885TLR8 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.